Research Papers:

High-sensitivity modified Glasgow prognostic score (HS-mGPS) Is superior to the mGPS in esophageal cancer patients treated with chemoradiotherapy

Peng Chen, Min Fang, Qiuyan Wan, Xuebang Zhang, Tao Song and Shixiu Wu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:99861-99870. https://doi.org/10.18632/oncotarget.21734

Metrics: PDF 1154 views  |   HTML 1870 views  |   ?  


Peng Chen1,*, Min Fang2,*, Qiuyan Wan3, Xuebang Zhang4, Tao Song2 and Shixiu Wu1

1Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou 310000, Zhejiang, P. R. China

2Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310000, Zhejiang, P. R. China

3Department of Gynecologic Oncology, Jiangxi Cancer Hospital, Nanchang 330029, Jiangxi, P. R. China

4Department of Radiation Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, P. R. China

*These authors contributed equally to this work

Correspondence to:

Shixiu Wu, email: [email protected], [email protected]

Keywords: esophageal squamous cell carcinoma, Glasgow prognostic score, prognostic factor, treatment response, survival

Received: July 17, 2017     Accepted: September 21, 2017     Published: October 11, 2017


The present study compared the prognostic value of the modified Glasgow prognostic score (mGPS) and high-sensitivity mGPS (HS-mGPS) in unresectable locally advanced esophageal squamous cell carcimona (LAESCC) patients treated with concurrent chemoradiotherapy (CCRT). The baseline data of 163 eligible patients were retrospectively collected. Patients with a C-reactive protein (CRP) ≤ 10 mg/l and albumin ≥ 35 g/l were allocated to mGPS-0 group. Patients with only elevated CRP (> 10 mg/l) were assigned to mGPS-1 group. Patients who had both elevated CRP (> 10 mg/l) and hypoalbuminurea (< 35 g/l) were assigned to mGPS-2 group. The HS-mGPS was calculated based on cutoff values of 3mg/l for CRP and the same value (35 g/l) for albumin. Prognostic significance for both tumor response and overall survival (OS) was analyzed by univariate and multivariate analysis. The mGPS was 0 in 95 patients, 1 in 28 patient and 2 in 40 patients. In contrast, the HS-mGPS was 0 in 66 patients, 1 in 47 patients and 2 in 50 patients. In multivariate analysis, the HS-mGPS was the only positive factor for tumor response (P = 0.015). Both the mGPS (P < 0.001) and HS-mGPS (P < 0.001) were good prognostic predictors for OS. However, the HS-mGPS was found to be a superior prognostic predictor compared to the mGPS in a multivariate analysis (P = 0.006). In conclusion, the pretreatment HS-mGPS is a strong prognosticator superior to the mGPS for both tumor response and OS in LAESCC patients who received CCRT.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21734